Acrivon Therapeutics
ACRV
ACRV
62 hedge funds and large institutions have $45.7M invested in Acrivon Therapeutics in 2025 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 16 increasing their positions, 22 reducing their positions, and 7 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
less ownership
Funds ownership: →
less repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
67% less capital invested
Capital invested by funds: $140M → $45.7M (-$94.3M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Holders
62
Holding in Top 10
–
Calls
–
Puts
–
Top Buyers
| 1 | +$92.6K | |
| 2 | +$71.7K | |
| 3 | +$29.6K | |
| 4 |
PCM
Prelude Capital Management
New York
|
+$26.5K |
| 5 |
IIM
INTECH Investment Management
West Palm Beach,
Florida
|
+$20.5K |
Top Sellers
| 1 | -$677K | |
| 2 | -$455K | |
| 3 | -$365K | |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$299K |
| 5 |
UOC
UBS O'Connor
Chicago,
Illinois
|
-$177K |
